您好,欢迎来到试剂信息网! [登录] [免费注册]
试剂信息网
位置:首页 > 产品库 > Larotrectinib(LOXO-101 ARRY-470)
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
Larotrectinib(LOXO-101 ARRY-470)
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
Larotrectinib(LOXO-101 ARRY-470)图片
CAS NO:1223403-58-4
规格:≥98%
包装与价格:
包装价格(元)
5mg电议
10mg电议
25mg电议
50mg电议
100mg电议
250mg电议
500mg电议

产品介绍
理化性质和储存条件
Molecular Weight (MW)428.44
FormulaC21H22F2N6O2
CAS No.1223403-58-4 (free base);
Storage-20℃ for 3 years in powder form
-80℃ for 2 years in solvent
Solubility (In vitro)DMSO: 100 mg/mL (189.9 mM)
Water: <1 mg/mL
Ethanol: 100 mg/mL (189.9 mM)
SMILESO=C(N1CC[C@@H](C1)O)NC2=C3N=C(N4CCC[C@@H]4C5=CC(F)=CC=C5F)C=CN3N=C2
SynonymsARRY-470, Larotrectinib; LOXO 101; LOXO-101; LOXO101; ARRY-470; ARRY470; ARRY 470; trade name: Vitrakvi
实验参考方法
In Vitro

In vitro activity: Larotrectinib (formerly known as LOXO-101, ARRY-470) is a potent, orally bioactive, highly selective, ATP competitive TRK inhibitor with IC50s in low nanomolar range (2 to 20 nM) for inhibition of all TRK family members in binding and cellular assays. It has 100x selectivity over other kinases, and is with 2 to 20 nM cellular potency against the TRKA, TRKB, and TRKC kinases. LOXO-101 was evaluated for off-target kinase enzyme inhibition against a panel of non-TRK kinases at a concentration of 1,000 nM and ATP concentrations around the Km. Preclinical models of LOXO-101 using TRK-fusion-bearing human-derived cancer cell lines demonstrate inhibition of the fusion oncoprotein and cellular proliferation in vitro, and tumor growth in vivo.


Kinase Assay: LOXO-101 is a small molecule that was designed to block the ATP binding site of the TRK family of receptors, with 2 to 20 nM cellular potency against the TRKA, TRKB, and TRKC kinases. IC50 value: 2 - 20 nM Target: TRKA/B/C in vitro: LOXO-101 is an orally administered inhibitor of the TRK kinase and is highly selective only for the TRK family of receptors. LOXO-101 is evaluated for off-target kinase enzyme inhibition against a panel of 226 non-TRK kinases at a compound concentration of 1,000 nM and ATP concentrations near the Km for each enzyme. In the panel, LOXO-101 demonstrates greater than 50% inhibition for only one non-TRK kinase (TNK2 IC50, 576 nM). Measurement of proliferation following treatment with LOXO-101 demonstrates a dose-dependent inhibition of cell proliferation in all three cell lines. The IC50 is less than 100 nM for CUTO-3.29 and less than 10 nM for KM12 and MO-91, consistent with the known potency of this drug for the TRK kinase family.


Cell Assay: Ba/F3 cells expressing MPRIP-NTRK1 (RIP-TRKA) or EV were lysed after 5 h of treatment with the indicated doses of drugs (ARRY-470; G, gefitinib 1,000 nM) or DMSO control. The cell lysate are used for western bolt analysis.

In VivoEarly/sustained but not late/acute administration of ARRY-470(LOXO-101) markedly attenuates bone cancer pain and significantly blocks the ectopic sprouting of sensory nerve fibers and the formation of neuroma-like structures in the tumor bearing bone, but does not have a significant effect on tumor growth or bone remodeling. It has very limited ability crossing of the blood brain barrier.
Animal modelAdult male C3H/HeJ mice
Formulation & DosageFormulated in Labrafac;polygly-colyzed glyceride; 10-100 mg/kg; p.o.
ReferencesMol Pain. 2010 Dec 7;6:87. doi: 10.1186/1744-8069-6-87; Nat Med. 2013 Nov;19(11):1469-72.